AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

IQE PLC

Director's Dealing Jul 29, 2022

7718_dirs_2022-07-29_272233fd-9f76-4722-9372-138f198c10cb.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 1532U

IQE PLC

29 July 2022

IQE plc

Cardiff, UK

29 July 2022

Director/PDMR Shareholding

IQE plc (AIM:  IQE, "IQE" or the "Group"), the leading supplier of compound semiconductor wafer products and advanced material solutions to the global semiconductor industry, was notified on 27 July 2022 that Dr Drew Nelson, President and Non-Executive Director of the Company, has extended his sale and repurchase agreement with Equities First Holdings ("EFH") for 11,000,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") ("EFH Sale Shares") (the "Agreement") together with an additional 1,121,711 Ordinary Shares, the subject of a margin call as per the announcement on 11 May 2020 (the "Margin Call Shares").

As first announced on 6 August 2019, under the original terms of the Agreement, Dr Nelson was obligated to repurchase (and EFH was obligated to sell to Dr Nelson) the EFH Sale Shares at the end of a three year term, ending on 02 August 2022.  Dr Nelson has now extended the Agreement with EFH such that the total term is now five years, ending on 5 August 2024. At the same time, EFH will return the Margin Call Shares. The price at which Dr Nelson is required to repurchase the EFH Sale Shares remains 43.96 pence per share. All other terms under the Agreement, as disclosed on 6 August 2019, remain the same. 

Dr Nelson maintains a beneficial interest in 40,567,234 Ordinary Shares, representing 5.04% of the Company's issued share capital.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1. Details of the Person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA")
a) Name Dr Andrew Nelson
2. Reason for the notification
a) Position / status PDMR (Non-Executive Director)
b) Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name IQE plc
b) Legal Entity Identifier 213800Y33WHD3ESJJP16
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument Ordinary shares of 1 pence each in the Company



GB0009619924
b) Nature of the transaction 1)  Extension of a repurchase agreement with Equities First Holdings for 11,000,000 Ordinary Shares from 2 August 2022 to 5 August 2024

2)  Extension of deposit of 1,121,711 Ordinary Shares from 2 August 2022 to 5 August 2024
c) Price(s) and volume(s) 1)  11,000,000 ordinary shares at 43.96 pence per share

2)  1,121,711 Ordinary Shares at nil consideration
d) Aggregated information

·      Aggregated volume

·      Aggregated price
1)  11,000,000 ordinary shares at 43.96 pence per share

2)  1,121,711 Ordinary Shares at nil consideration
e) Date of the transaction(s) 26 July 2022
f) Place of the transaction Outside a trading venue

Contacts:

IQE plc

+44 (0) 29 2083 9400

Americo Lemos

Tim Pullen

Amy Barlow

Peel Hunt LLP (Nomad and Joint Broker)

+44 (0) 20 7418 8900

Edward Knight

Paul Gillam

James Smith

Citigroup Global Markets Limited (Joint Broker)

+44 (0) 20 7986 4000

Christopher Wren

Peter Catterall

Headland Consultancy (Financial PR)

+ 44 (0) 20 38054822

Andy Rivett-Carnac: +44 (0) 7968 997 365

Antonia Pollock: +44 (0) 7789 954 356

ABOUT IQE

http://iqep.com

IQE is the leading global supplier of advanced compound semiconductor wafers and materials solutions that enable a diverse range of applications across:

·    handset devices

·    global telecoms infrastructure

·    connected devices

·    3D sensing

As a scaled global epitaxy wafer manufacturer, IQE is uniquely positioned in this market which has high barriers to entry. IQE supplies the whole market and is agnostic to the winners and losers at chip and OEM level. By leveraging the Group's intellectual property portfolio including know-how and patents, it produces epitaxy wafers of superior quality, yield and unit economics.

IQE is headquartered in Cardiff UK, with c. 685 employees across nine manufacturing locations in the UK, US, Taiwan and Singapore, and is listed on the AIM Stock Exchange in London.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBKFBKABKDKOB

Talk to a Data Expert

Have a question? We'll get back to you promptly.